AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02830685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)
Description: After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using a TCPM (TiLOOOP® Bra), either completely covering the implant or simply covering the anterior surface of it.The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
Study NCT02561468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Study NCT02561468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT00590772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: 10 mg po each day (compared to placebo for 2 weeks)
Study NCT00590772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 2 weeks
Study NCT02823067 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
Study NCT03078218 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Description: The tool evaluated will be the assumption of peripherical arterial oxygen saturation by pulse oximetry. The pulse oximetry will identify hypoxemic CCHD and hypoxemic non-cardiac disease before discharge.The test will be realised before 24 hours of life in a newborn aged at least of 35 weeks of gestation.
Study NCT00459732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: 25 mg of elemental zinc as zinc sulphate take once daily for 18 months
Study NCT00459732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, identical to the zn capsule in size, shape and color, taken once daily for 18 months
Study NCT01235741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide+Metreleptin
Description: Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.
Study NCT01235741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
Study NCT01833156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoistureMeterD
Description: measuring erythema size and the dielectric constant values
Study NCT03284307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 20 participants will be administered Dexmedetomidine.
Study NCT03284307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 20 participants will be administered Ketamine.
Study NCT03284307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 20 participants will be administered Propofol.
Study NCT03284307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 20 participants will be administered Midazolam.
Study NCT03188497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: Lobaplatin for Injection
Study NCT03188497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: linear accelerator
Description: Medical linear accelerator
Study NCT04491513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography angiography
Description: Computed tomography angiography for the detection of proximal coronary lesions in patients in the work-up for TAVI
Study NCT02560545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis oil
Description: Cannabis oil 20% THC
Study NCT02560545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis oil
Description: Cannabis oil 20% THC
Study NCT02122757 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cefaly tDCS
Description: Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
Study NCT02122757 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham Cefaly tDCS
Description: 2mA during 30sec
Study NCT03983317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Empower Neuromodulation System
Description: Transcutaneous electrical nerve stimulation
Study NCT00632606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate
Description: magnesium sulfate 2 grams intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
Study NCT00632606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: metoclopramide 10 mg intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
Study NCT00580528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Internet Newsletters
Description: Tailored newsletters delivered via the Internet with content for improving eating and activity to reduce blood pressure
Study NCT00580528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored print newsletters delivered via mail
Description: Tailored Newsletters with content to improve eating and activity to reduce blood pressure
Study NCT04141904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 MG [Xeljanz]
Description: Tofacitinib 5mg capsules twice a day for 7-10 days
Study NCT04141904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules twice a day for 7-10 days
Study NCT01041963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Patients with hypertension will take 20-40mg enalapril per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Study NCT01041963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril plus Losartan
Description: Patients with hypertension will take 20-40mg enalapril plus 25-50mg losartan per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Study NCT01041963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Study NCT01694498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A: Desmopressin 25 µg
Study NCT01694498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B. Desmopressin 50 µg
Study NCT01694498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00588497 — intervention group
Intervention type: PROCEDURE
Intervention: Micro-insert hysteroscopic sterilization
Description: Placement of micro-inserts transcervically with the aid of a hysteroscope
Study NCT00588497 — intervention group
Intervention type: RADIATION
Intervention: Plain abdominal Xray
Description: Performed immediately after micro-inserts placement and at 3 months
Study NCT00588497 — intervention group
Intervention type: PROCEDURE
Intervention: Pelvic Ultrasound
Description: Performed immediately after micro-inserts placement and at 3 months.
Study NCT00588497 — intervention group
Intervention type: RADIATION
Intervention: Hysterosalpingogram
Description: Performed 3 months after micro-inserts placement
Study NCT00145158 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8 HLA-A2-restricted peptides and Montanide ISA51
Study NCT00145158 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8 HLA-A2-restricted peptides and CpG 7909
Study NCT04870489 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin and CO2 laser
Description: Patients must complete at least 2 months of Isotretinoin prior to starting the study and then continue it for the duration of the 3 months of treatment with the CO2 laser.
Study NCT04870489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Co2 laser
Description: After 6-12 months of no treatment for acne the patient comes to do second side of face only laser treatment
Study NCT00790140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prosure
Description: This is an enteral tube feed with 125 kcals \& 6.65g protein per 100mls. It contains Fat, Carbohydrate, and vitamins and minerals and is enriched with 2.2g Eicosapentaenoic Acid per 500mls of feed. Patients on this trial who are randomized to Prosure will receive the product orally for 5 days prior to surgery and for 21 days post surgery vis a feeding jejunostomy tube
Study NCT00790140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ensure Plus
Description: This is a standard enteral tube feed with 150 kcals \& 6.3 g protein per 100mls as well as carbohydrate, fat and vitamins and minerals. It does not have any active immunonutrients. Patients randomized to this arm will receive the product for 5 days pre op and 21 days post surgery via a feeding jejunostomy tube
Study NCT02942459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: 25 Weekly Hours of Music Therapy by an Educated Music Therapist
Study NCT02942459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Listening
Description: 25 weekly Hours of Being Together with an unknown Care Staff Member
Study NCT03800147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mutaflor Suspension (E. coli Nissle 1917)
Description: Inoculation of Mutaflor Suspension (E. coli Nissle 1917)
Study NCT03800147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Blood samples will be collected and analyzed at different study time points
Study NCT03800147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stool samples
Description: Stool samples will be collected and analyzed at different study time points
Study NCT03800147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical information
Description: Clinical information will be collected at different study time points using questionnaires
Study NCT00689507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: monoclonal antibody
Study NCT02146534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release fampridine
Description: pts will receive Fampyra 10 mg BID PO for the duration of the study
Study NCT02146534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo will be taken PO BID
Study NCT02873702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole delayed-release capsules.
Study NCT02873702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules.
Study NCT02873702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules.
Study NCT00452816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace Solutions Consulting approach
Description: Consulting process includes:~1. baseline measure of best practices~2. gap analysis and recommendations reporting~3. delivery of solution set toolkits for each practice chosen for implementation
Study NCT00452816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed intervention
Description: Abbreviated version of the Workplace Solutions Consulting process applied in the intervention group
Study NCT04952948 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: PILATES Training
Description: During the PILATES sessions, the practitioner received orientations to to perform slow movements, aware, and combined with the respiratory cycle. The exercises program was performed on a soft ground covered with tatamis. During the program, a set of swiss balls of 45, 55, and 65 cm in size and elastic bands of very moderate resistance were used. Each exercise session was divided into 3 stages, namely (a) global initial static and dynamic stretching (10 minutes); (b) general conditioning (45 minutes) and; (c) relaxation (5 minutes). The amount of series and repetitions per set in exercises, in addition to the intensity required in each session in PILATES is presented in Table 2 of Melo et al. (2020) - Vide reference.
Study NCT04952948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILATES Training
Description: During the PILATES sessions, the practitioner received orientations to to perform slow movements, aware, and combined with the respiratory cycle. The exercises program was performed on a soft ground covered with tatamis. During the program, a set of swiss balls of 45, 55, and 65 cm in size and elastic bands of very moderate resistance were used. Each exercise session was divided into 3 stages, namely (a) global initial static and dynamic stretching (10 minutes); (b) general conditioning (45 minutes) and; (c) relaxation (5 minutes). The amount of series and repetitions per set in exercises, in addition to the intensity required in each session in PILATES is presented in Table 2 of Melo et al. (2020) - Vide reference.
Study NCT02749084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T reg DLI
Description: Purified Treg cells will be obtained from the original HSC donor (T reg DLI).~Tregs preparation will start with unstimulated donor leukapheresis from the original stem cell donor.~The apheresis product will be provided to the Cell Factory Calori,Milano, where T reg purification will take place.~T reg cells will be PURIFIED utilizing the CliniMACS Plus Systems for depletion of CD8 and CD19 positive cells and enrichment for CD25high cells.~Release Criteria of Treg cell preparation will be defined.~The product will be infused into the recipient through a venous catheter.
Study NCT03791957 — intervention group
Intervention type: OTHER
Intervention: Blood Haemoglobin
Description: Routine haemotological investigation of blood haemoglobin levels in gm/dL will be recorded from withdrawn venous blood
Study NCT02637492 — intervention group
Intervention type: OTHER
Intervention: Collection of clinical signs and symptoms
Description: Collection of clinical signs and symptoms used for developing a Clinical prediction rule of critical lower limb ischaemia (diagnosed by haemodynamic methods: ankle pressure, toe pressure-laser Doppler or photo-plethysmography, transcutaneous oxygen pressure) in patients with peripheral occlusive arterial disease
Study NCT00950859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 (Cohort I)
Description: 50 mg once daily
Study NCT00950859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 (Cohort II)
Description: 50 mg twice daily
Study NCT03398083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: THC capsule
Study NCT03398083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THC
Description: THC capsule
Study NCT03398083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Alpraxolam capsule
Study NCT03398083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alprazolam
Description: Alpraxolam capsule
Study NCT03398083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: Sugar pill capsule
Study NCT03398083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: CBD capsule
Study NCT03398083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBD
Description: CBD capsule
Study NCT00850239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutogliptin
Description: 400 mg
Study NCT00850239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04320589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement \& a bolus of 40 mg/kg MgSo₄ is given I.V. \& may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached (7\&10). Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient
Study NCT04320589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthetic
Description: 1) Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ \& β-adrenergic blockers \[Prazocin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day \&/or Labetalol (Trandate)200-600 mg/day, ACI \& ACRB e.g. Tritace 2.5-10 mg/day \& Atacand 4-16 mg/day\]
Study NCT00839319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 ug/kg subcutaneous injections on Day 1.
Study NCT00839319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo hCG (no active ingredient)
Description: placebo hCG
Study NCT00839319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG (human chorionic gonadotropin)
Description: 15 IU subcutaneous injection every other day for 10 days (5 doses)
Study NCT00839319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG (human chorionic gonadotropin)
Description: 60 IU subcutaneous injection
Study NCT00839319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG (human chorionic gonadotropin)
Description: 125 IU subcutaneous injection
Study NCT00839319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: 75 mg testosterone gel applied transdermally for 10 days
Study NCT05804617 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dome-type (Modified C-incision) manual morcellation
Description: Morcellation performed by surgeon or trainee
Study NCT05804617 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dome-type (Modified C-incision) manual morcellation
Description: Morcellation performed by surgeon or trainee
Study NCT00876551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic vacuum assisted closure
Description: 1. Endoscopic debridement of wound using a regular biopsy forceps.~2. Introduction via the nose and oral exteriorization of a silicone duodenal tube (Freka Tube, 15 Ch, Fresenius Kabi, Bad Homburg v.d. H. Germany)~3. Fixation of a polyurethane foam (sponge, pore size 400-600 µm, KCI, Wiesbaden Germany) to the tip of the duodenal tube with a mersilene suture (0,35mm, Johnson \& Johnson, St-Stevens-Woluwe, Belgium).~4. Trimming of the sponge to the specific wound size.~5. Endoscopic placement of the sponge in the intrathoracic leak with a grasping forceps (Olympus, Germany)~6. Application of continuous suction of 125mmHg using vacuum pump (KCI, Wiesbaden Germany).~7. Sponge exchange twice a week until wound grounds are clean and closed
Study NCT00575640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
Study NCT03005015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Study NCT03005015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study NCT01571518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: late leukostim
Description: injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
Study NCT01571518 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: early leukostim
Description: injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
Study NCT00345748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
Study NCT00345748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
Study NCT02399163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride free toothpaste
Description: Brushing with fluoride free toothpaste
Study NCT02399163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride free toothpaste
Description: Brushing with fluoride free toothpaste
Study NCT02399163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste
Description: Brushing with fluoride containing toothpaste
Study NCT02399163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride toothpaste
Description: Brushing with fluoride containing toothpaste
Study NCT02399163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride mouthwash
Description: Fluoride mouth wash to be followed after brushing with fluoride free toothpaste in Placebo dentifrice/Fluoride rinse arm and in Fluoride dentifrice/Fluoride rinse arm